- Home
- DCBO vs ARVN Comparison
DCBO vs ARVN Comparison
Compare DCBO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCBO
- ARVN
- Stock Information
- Founded
- DCBO 2016
- ARVN 2015
- Country
- DCBO Canada
- ARVN United States
- Employees
- DCBO N/A
- ARVN N/A
- Industry
- DCBO
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- DCBO
- ARVN Health Care
- Exchange
- DCBO Nasdaq
- ARVN Nasdaq
- Market Cap
- DCBO 723.3M
- ARVN 676.2M
- IPO Year
- DCBO 2020
- ARVN 2018
- Fundamental
- Price
- DCBO $23.91
- ARVN $11.38
- Analyst Decision
- DCBO Strong Buy
- ARVN Buy
- Analyst Count
- DCBO 8
- ARVN 23
- Target Price
- DCBO $39.38
- ARVN $17.75
- AVG Volume (30 Days)
- DCBO 85.5K
- ARVN 2.6M
- Earning Date
- DCBO 11-07-2025
- ARVN 11-05-2025
- Dividend Yield
- DCBO N/A
- ARVN N/A
- EPS Growth
- DCBO 32.42
- ARVN N/A
- EPS
- DCBO 0.74
- ARVN N/A
- Revenue
- DCBO $236,691,000.00
- ARVN $312,300,000.00
- Revenue This Year
- DCBO $13.00
- ARVN N/A
- Revenue Next Year
- DCBO $8.37
- ARVN N/A
- P/E Ratio
- DCBO $29.77
- ARVN N/A
- Revenue Growth
- DCBO 13.16
- ARVN 93.86
- 52 Week Low
- DCBO $22.79
- ARVN $5.90
- 52 Week High
- DCBO $53.86
- ARVN $28.76
- Technical
- Relative Strength Index (RSI)
- DCBO 30.49
- ARVN 73.09
- Support Level
- DCBO $22.79
- ARVN $9.27
- Resistance Level
- DCBO $25.41
- ARVN $10.18
- Average True Range (ATR)
- DCBO 0.97
- ARVN 0.47
- MACD
- DCBO -0.24
- ARVN 0.09
- Stochastic Oscillator
- DCBO 11.97
- ARVN 94.47
About DCBO Docebo Inc.
Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.